Comparative Pharmacology
Head-to-head clinical analysis: FLUDROCORTISONE ACETATE versus LOTEPREDNOL ETABONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUDROCORTISONE ACETATE versus LOTEPREDNOL ETABONATE.
FLUDROCORTISONE ACETATE vs LOTEPREDNOL ETABONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mineralocorticoid receptor agonist; promotes sodium reabsorption and potassium excretion in renal distal tubules, increasing extracellular fluid volume. Also has glucocorticoid activity.
Corticosteroid with high glucocorticoid receptor affinity; reduces inflammation by inhibiting phospholipase A2, decreasing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
0.1 mg orally once daily, range 0.05-0.2 mg/day
0.5% ophthalmic suspension: 1-2 drops into affected eye(s) four times daily. In severe cases, may be increased to 1-2 drops every hour during the first week, then taper.
None Documented
None Documented
Terminal elimination half-life is 3.5 hours (range 2–5 h); clinical effect duration exceeds half-life due to mineralocorticoid receptor binding.
Terminal elimination half-life is 2.2-4.3 hours; clinical context: supports twice-daily dosing in ophthalmic use, with minimal systemic accumulation.
Renal (80%) as inactive metabolites; less than 5% unchanged; minor biliary/fecal elimination.
Primarily hepatic metabolism; metabolites excreted in urine (approximately 80% as inactive metabolites) and feces (15-20%). Less than 1% excreted unchanged in urine.
Category D/X
Category C
Corticosteroid
Corticosteroid